Weintraub Daniel, Chen Peijun, Ignacio Rosalinda V, Mamikonyan Eugenia, Kales Helen C
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA.
Arch Neurol. 2011 Jul;68(7):899-904. doi: 10.1001/archneurol.2011.139.
Antipsychotic (AP) use is common in Parkinson disease (PD), but APs can worsen parkinsonism, evidence for efficacy is limited, and use in patients with dementia increases mortality.
To examine the frequency and characteristics, including changes over time, of AP use in a large cohort of patients with PD.
Using Veterans Affairs data from fiscal year (FY) 2008, rates and predictors of AP prescribing were determined for patients with PD and psychosis stratified by dementia status (N = 2597) and a comparison group of patients with dementia and psychosis without PD (N = 6907). Fiscal year 2008 and FY2002 data were compared to examine changes in AP prescribing over time.
Department of Veterans Affairs outpatient facilities.
Outpatients with PD and psychosis and outpatients without PD with dementia and psychosis, all receiving care at Veterans Affairs facilities in FY2002 and FY2008.
Antipsychotic prescribing, including overall, class, and specific medications.
In FY2008, 50% of patients with PD having a diagnosis of psychosis were prescribed an AP. Among treated patients, the atypical AP quetiapine was most frequently prescribed (66%), but approximately 30% received high-potency APs. Clozapine was rarely prescribed (<2%). In multivariate models, diagnoses of PD and dementia were associated with AP use. Comparing FY2008 with FY2002, AP use in PD was unchanged, with decreases in risperidone and olanzapine use offset by an increase in quetiapine prescribing and the introduction of aripiprazole.
Half of the patients with PD and psychosis receive APs, not uncommonly high-potency agents associated with worsening parkinsonism, and frequency of use has been unchanged since the "black box" warning for AP use in patients with dementia was issued. Recent trends are a shift to quetiapine use and the common use of aripiprazole. As psychosis and dementia are frequently comorbid in PD, safety risks associated with AP use in this population need to be assessed.
抗精神病药物(AP)在帕金森病(PD)患者中使用普遍,但AP会加重帕金森症状,其疗效证据有限,且在痴呆患者中使用会增加死亡率。
研究一大群PD患者中AP使用的频率和特征,包括随时间的变化。
利用2008财年退伍军人事务部的数据,确定了按痴呆状态分层的PD合并精神病患者(N = 2597)以及无PD的痴呆合并精神病患者对照组(N = 6907)的AP处方率和预测因素。比较了2008财年和2002财年的数据,以研究AP处方随时间的变化。
退伍军人事务部门诊设施。
2002财年和2008财年在退伍军人事务部设施接受治疗的PD合并精神病门诊患者以及无PD的痴呆合并精神病门诊患者。
抗精神病药物处方,包括总体、类别和具体药物。
2008财年,50%诊断为精神病的PD患者开具了AP。在接受治疗的患者中,非典型AP喹硫平的处方最为频繁(66%),但约30%的患者接受了高效能AP。氯氮平的处方很少(<2%)。在多变量模型中,PD和痴呆的诊断与AP使用相关。将2008财年与2002财年进行比较,PD患者中AP的使用没有变化,利培酮和奥氮平使用的减少被喹硫平处方的增加和阿立哌唑的引入所抵消。
一半的PD合并精神病患者接受AP治疗,使用高效能药物(这通常会加重帕金森症状)并不罕见,自对痴呆患者使用AP发出“黑框”警告以来,使用频率一直没有变化。近期趋势是转向使用喹硫平以及普遍使用阿立哌唑。由于精神病和痴呆在PD中经常合并存在,需要评估该人群中使用AP的安全风险。